Emergent biosolution stock.

Jul. 31, 2023, 05:14 PM. Emergent Biosolutions Inc (NYSE:EBS) shares are trading higher in Monday's after-hours session after the company was awarded a 10-year contract for development of an Ebola ...For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned. ... accused Emergent executives of inflating the company's stock price by ...What happened. Shares of Emergent Biosolutions ( EBS -0.48%) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion ...May 10, 2023 · Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses.

Emergent Biosolutions belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ultragenyx RARE , closed the last trading session 3.7% higher at $39.07.

Aug 8, 2023 · Emergent BioSolutions Contacts: Media: Matt Hartwig Senior Director, Media Relations 240-760-0551 [email protected] Investors: Rich Lindahl Executive Vice President & Chief Financial Officer 240-631-3360 [email protected]. Source: Emergent BioSolutions During the last session, Emergent Biosolutions Inc (NYSE:EBS)’s traded shares were 2.4 million, with the beta value of the company hitting 1.01. At the end of the trading day, the stock’s price was $2.14, reflecting an intraday loss of -0.47% or -$0.01. The 52-week high for the EBS share is $16.

View Emergent Biosolutions Inc EBS investment & stock information. Get the latest Emergent Biosolutions Inc EBS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.GAITHERSBURG, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2021. "Emergent’s performance in 2021 is a testament to our strategic focus and highly capable team," said Robert G. Kramer, president and CEO of Emergent …Aug 2, 2022 · What happened. Shares of Emergent BioSolutions ( EBS -1.91%) are sinking today, down 11.8% as of 11:27 a.m. ET. The decline came after the company announced its second-quarter financial results ... Emergent BioSolutions: Stellar Acting Stock TraderMark Wed, Oct. 22, 2008 3 Comments. Emergent BioSolutions: Surprising Value Play Saj Karsan Fri, Sep. 12, 2008 1 Comment. 1 2 Next. People Also ...

Historical daily share price chart and data for Emergent Biosolutions since 2006 adjusted for splits and dividends. The latest closing stock price for Emergent Biosolutions as of …

What happened. Shares of Emergent BioSolutions (EBS-4.11%) were sinking 12.8% lower as of 10:53 a.m. ET on Friday. The decline came after J.P. Morgan …

A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...Emergent Biosolutions (NYSE: EBS) is owned by 79.75% institutional shareholders, 93.92% Emergent Biosolutions insiders, and 0.00% retail investors. Fuad Elhibri is the largest individual Emergent Biosolutions shareholder, owning 25.73M shares representing 49.67% of the company. Fuad Elhibri's Emergent Biosolutions shares are currently …Analyst Recommendations on Emergent BioSolutions Inc. Benchmark Downngrades Emergent Biosolutions to Hold From Buy. Aug. 29. MT. Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $22. Apr. 10. MT. JPMorgan Downgrades Emergent Biosolutions to Underweight From Neutral, Adjusts Price Target to $9 From …Based on short-term price targets offered by two analysts, the average price target for Emergent Biosolutions comes to $13.50. The forecasts range from a low of $5.00 to a high of $22.00. The ...Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Rapt Therapeutics RAPT, another stock in the same industry, closed the last trading session 2.7% higher at ...Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody Subscribe to newsletters Subscribe: $29.99/year

Emergent has secured an agreement with Sandoz to distribute an authorized generic of NARCAN® (naloxone HCl) Nasal Spray 4mg, which will be available to people in the U.S. via retail pharmacies and institutions, including hospitals. This agreement will allow Emergent to continue supporting the public interest sector, where those communities and ...What happened. Shares of Emergent Biosolutions ( EBS -0.48%) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion ...Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%.Emergent Biosolutions EBS shares ended the last trading session 12.5% higher at $14.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.As you can see below, at the end of December 2022, Emergent BioSolutions had US$1.41b of debt, up from US$847.1m a year ago. Click the image for more detail. However, because it has a cash reserve of US$651.1m, its net debt is less, at about US$754.7m. NYSE:EBS Debt to Equity History April 5th 2023.

Emergent Biosolutions Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EBS updated stock price target summary.EBS Price Action: Emergent Biosolutions has a 52-week high of $45.02 and a 52-week low of $7.74. The stock was up 18.9% at $10.59 at time of publication, according to Benzinga Pro. Photo: courtesy ...

Has the stock finally bottomed out? Shares of drug manufacturer Emergent BioSolutions ( EBS -4.07%) are down 75% in the past 12 months. Investors have been turning to safer investments amid the ...Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola. GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced ...A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...Between March 2020 and February 2022, vaccine-maker Emergent BioSolutions was forced to discard or destroy up to 400 million doses' worth of the key component of both Johnson & Johnson's and ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Feb 27, 2023 · Emergent Biosolutions (EBS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.32. This compares to earnings of $4.50 per share a year ago.

Our Mission. At Emergent, we develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics worldwide. For 25 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared, just in case they ever do.

132. Last summer, investors flocked to the biotech company Emergent BioSolutions. The host of CNBC’s “Mad Money,” Jim Cramer, gushed about the Maryland business, which had secured a ...

10 stocks we like better than Emergent BioSolutions When o ur analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock ...For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned. ... accused Emergent executives of inflating the company's stock price by ...See the latest Emergent BioSolutions Inc stock price (EBS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.Emergent aims to price over-the-counter Narcan at about $50. Get Emergent BioSolutions Inc (EBS.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading ...Emergent Biosolutions Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time EBS stock price. Nov 5, 2021 · What happened. Shares of Emergent Biosolutions ( EBS -0.48%) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion ... Investors ran up stock in Gaithersburg, Maryland-based Emergent BioSolutions Wednesday, after the U.S. Food and Drug Administration approved opioid overdose treatment Narcan for over-the-counter ...Emergent BioSolutions reinstated with an Underweight at JPMorgan November 20, 2023TipRanks. Mixed Financial Outlook for Emergent Biosolutions: Strong Narcan Sales Offset by Lowered Guidance and ...Emergent BioSolutions Stock Forecast. Is Emergent BioSolutions Stock Undervalued? The current Emergent BioSolutions [ EBS] share price is $2.09. The Score for EBS is 37, which is 26% below its historic median score of 50, and infers higher risk than normal. EBS is currently trading in the 30-40% percentile range relative to its historical Stock ...Emergent aims to price over-the-counter Narcan at about $50. Get Emergent BioSolutions Inc (EBS.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading ...

Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 19.5% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $12.56 and a low of $9.47. Over the last year, Emergent Biosolutions Inc has hit prices as high as $43.46 and as low as $7.74.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 37.08% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $7.77. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as …View Emergent Biosolutions Inc EBS investment & stock information. Get the latest Emergent Biosolutions Inc EBS detailed stock quotes, stock data, ...Aug 8, 2023 · Emergent BioSolutions Contacts: Media: Matt Hartwig Senior Director, Media Relations 240-760-0551 [email protected] Investors: Rich Lindahl Executive Vice President & Chief Financial Officer 240-631-3360 [email protected]. Source: Emergent BioSolutions Instagram:https://instagram. y. y.compare stock chartssusan b anthony coin wortholaplex target EBS earnings call for the period ending September 30, 2023. Image source: The Motley Fool. Emergent BioSolutions ( EBS 11.68%) Q3 2023 Earnings Call. Nov 08, 2023, 5:00 p.m. ET. paa dividendprice 1964 kennedy half dollar Why Emergent BioSolutions Stock Is Tumbling Today Motley Fool - Tue Aug 22, 10:42AM CDT . The healthcare stock will soon be booted from an index tracked by several ETFs. EBS: 2.09 (-0.48%) Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600 PR Newswire - Mon Aug 21, 5:01PM CDT free stock charts with indicators Emergent Biosolutions Inc (EBS) stock is trading at $8.58 as of 11:21 AM on Monday, Mar 27, an increase of $0.48, or 5.93% from the previous closing price of $8.10. The stock has traded between $8.24 and $8.62 so far today. Volume today is light. So far 425,778 shares have traded compared to average volume of 1,546,652 shares.The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts. Skip to main navigation ... and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date ...Feb 25, 2022 · Emergent BioSolutions (EBS-6.98%) ended the week on a down note. Shares of the company closed 6.2% lower on Friday after it provided its fourth-quarter update following the market close on Thursday.